NMFC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NMFC is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near short-term support in pre-market at 8.02, but the overall setup is still weak: bearish moving averages, negative MACD, and no strong proprietary buy signal. Analyst sentiment is mostly cautious to negative, and the recent news shows one large investor, Ares, fully exited NMFC. For an impatient investor who does not want to wait for a better entry, this is still not a clear buy; I would hold off.
Current trend is bearish to neutral. MACD histogram is -0.0431 and still below zero, though slightly improving. RSI_6 at 40.575 is neutral but leaning weak, not oversold enough to signal a strong reversal. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms the stock remains in a downtrend. Pre-market price is 8.02, sitting just above support at 7.91 and below pivot 8.128, which suggests limited upside confirmation right now. The short-term pattern data also points to weakness over the next week before potential month-long stabilization.
["Insiders are buying, and buying activity increased 859.84% over the last month.", "Pre-market price is close to support around 7.91, which could attract value-oriented buyers.", "Monthly pattern estimate suggests a possible 3.46% gain over the next month."]
["Ares Management sold its entire NMFC stake, including a $477 million asset portfolio exit in February.", "Multiple analysts have cut price targets recently.", "BofA rates the stock Underperform and lowered its target to $7.50.", "Technical trend remains bearish with SMA_200 > SMA_20 > SMA_5 and negative MACD.", "No AI Stock Picker or SwingMax buy signal is present."]
Financial snapshot data was unavailable due to an error, so a quarter-by-quarter financial assessment cannot be completed from the provided data. The latest referenced quarter was Q4 2025, and analyst commentary described it as mixed, with strategic progress offset by balance sheet pressure, near-term earnings headwinds, markdown pressure on NAV, and reliance on fee waivers. That suggests growth and earnings quality are not yet strong enough for a confident long-term buy.
Analyst sentiment has trended downward. Since late February and March 2026, several firms cut price targets, including Wells Fargo, B. Riley, Keefe Bruyette, Lucid Capital, and BofA. Ratings are mostly Neutral/Market Perform/Equal Weight, with BofA the most negative at Underperform and a $7.50 target. The Wall Street pros view is therefore cautious: some see valuation improvement and strategic progress, but the broader view is that balance sheet pressure, earnings headwinds, and limited near-term catalysts remain concerns.
